$0.953
-0.072 (-7.52%)Al cierre
Noticias de AXNX
Eventos de AXNX
Axonex AI Group Trading Halted, News Pending
Axonex AI Group Limited trading halted, news pending
Axonics reports Q3 EPS 0c, consensus 13c
Reports Q3 revenue $116.2M, consensus $113.5M. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid(R) was driven by higher utilization at existing customers and the onboarding of new accounts."
Axonics receives regulatory approval for rechargeable SNM System in Australia
Axonics announced that it has received regulatory approval from the Therapeutic Goods Administration for marketing the Axonics R20 rechargeable sacral neuromodulation system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20 also provides physicians and their patients with enhanced programming capabilities and expanded MRI labeling. Axonics expects to commence sales of the R20 to Australian customers in November.
Axonics prevails in patent infringement lawsuit with Medtronic
Axonics (AXNX) announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic (MDT) against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. "A jury of our peers recognized that Axonics' proprietary tined lead design and temperature sensor technology is differentiated from our competitor's intellectual property," said Raymond W. Cohen, chief executive officer. "As we have said since this case was first filed in late 2019, our view is that Medtronic's lawsuit was initiated to stifle competition, limit patient and physician choice, and protect the incumbent's monopoly in sacral neuromodulation. We are very pleased with the jury's finding and continue to remain focused on fulfilling our mission of positively impacting the lives of adults with bladder and bowel dysfunction."
Artículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.